INNOCARE - 2026 Self-examination report on insider trading of company stocks
InnoCare Pharma Limited
Nuocheng Jianhua Pharmaceutical Co., Ltd.
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9969)
Overseas regulatory announcement
This announcement is made by InnoCare Pharmaceuticals Limited (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to set forth the "Announcement on Board Resolutions" published by the company on the website of the Shanghai Stock Exchange, "Announcement on the Third Vesting Period of the First Granted Part and the Second Vesting Period of the Reserved Granted Part of the 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan", and "Announcement on the Voiding of the Partially Granted Restricted Stocks that have not yet vested" Announcement", "Announcement on the use of idle self-owned funds for cash management", "Self-examination report on insiders' buying and selling of company stocks under the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan", "List of first-time incentive recipients of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (as of the first grant date)", "Verification Opinions of the Remuneration Committee of the Board of Directors on the Third Vesting Period of the Initial Grant Part of the Science and Technology Innovation Board Restricted Stock Incentive Plan in 2023 and the List of Vesting Parties in the Second Vesting Period of the Reserved Grant Part", "Verification Opinions of the Board of Directors Remuneration Committee on the List of Incentive Objects of the First Grant of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan", "Shanghai Fangda Law Firm on InnoCare Pharma Limited)'s 2025 Annual General Meeting of Shareholders", "Shanghai Fangda Law Firm's Legal Opinion on InnoCare Pharma Limited's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan's First Grant Part's Third Vesting Period and Reserved Grant Part's Second Vesting Period Attribution Conditions Achievements and Certain Restricted Stock Invalidation Related Matters" and "Shanghai Fangda Law Firm's Legal Opinion on InnoCare Pharma Limited's 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan" Limited) Legal Opinion on Matters Related to the First Grant of the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan".
By order of the board of directors
Nuocheng Jianhua Pharmaceutical Co., Ltd.
Chairman and Executive Director
Dr. Cui Jisong
Hong Kong, June 16, 2026
As of the date of this announcement, the board of directors includes Dr. Cui Jisong, the chairman and executive director; Dr. Zhao Renbin, the executive director; Dr. Shi Yigong and Mr. Xie Ronggang, the non-executive directors; and Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang, the independent non-executive directors.
A-share code: 688428 A-share abbreviation: Nuocheng Jianhua Announcement number: 2026-030 Hong Kong stock code: 09969 Hong Kong stock abbreviation: Nuocheng Jianhua
Nuocheng Jianhua Pharmaceutical Co., Ltd.
About the Science and Technology Innovation Board Restricted Stock Incentive Plan
2026
Self-examination report on insider trading of company stocks
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
Innocent Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held a board meeting on April 24, 2026 to review and approve the "2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (Draft) and its Summary" and other relevant proposals, and disclosed relevant announcements on the Shanghai Stock Exchange website (www.sse.com.cn) on April 25, 2026.
In accordance with laws, regulations and normative documents such as the "Measures for the Administration of Equity Incentives of Listed Companies" (hereinafter referred to as the "Administration Measures"), the "Stock Listing Rules on the Shanghai Stock Exchange's Science and Technology Innovation Board", "Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 4 - Equity Incentive Information Disclosure" and other relevant provisions of the company's "Information Disclosure Management System" and "Insider Information Insider Registration Management System", the company through the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. Insiders of the 2020 Science and Technology Innovation Board Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan") conducted a self-examination on the purchase and sale of the company's stocks within 6 months before the public disclosure of the draft incentive plan (i.e., from October 25, 2025 to April 24, 2026, hereinafter referred to as the "Self-examination Period"). The specific circumstances are as follows:
Scope and procedures of verification
The verification objects are the insiders of the incentive plan (hereinafter referred to as the "verification objects"). 2. Insiders of the incentive plan filled in the "Insider Information Insider Registration Form".
The company inquired and confirmed with the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. about the purchase and sale of company stocks by the inspection target during the self-examination period, and the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. issued an inquiry certificate.
Explanation on the purchase and sale of company stocks by the subject of verification
According to the "Inquiry Certificate of Information Disclosure Obligor's Shareholdings and Changes in Shares" and the "Detailed List of Changes in Shareholders" issued by China Securities Depository and Clearing Co., Ltd., during the self-inspection of the incentive plan, a total of 1 verification subject purchased and sold the company's stocks.
After verification by the company, it is believed that the above-mentioned person’s transaction changes during the self-examination period were based on the company’s publicly disclosed information and his own judgment on the secondary market transactions. Before buying and selling the company’s stocks, he was not aware of the relevant information of this incentive plan, and no one leaked relevant information of this incentive plan to him or suggested that he buy or sell the company’s stocks based on this. There was no use of inside information for stock trading. Except for the above persons, none of the other persons subject to the inspection purchased or sold the company's stocks during the self-examination period.
- Conclusion
In the process of planning the incentive plan, the company strictly complied with the relevant provisions of the "Administrative Measures", the company's "Information Disclosure Management System" and the "Insider Information Insider Registration Management System", strictly limited the scope of personnel participating in the planning and discussion, promptly registered relevant company personnel and intermediaries who had access to inside information, and took corresponding confidentiality measures.
After verification, during the self-examination period of the incentive plan, none of the insiders used the inside information related to the company's incentive plan to buy or sell stocks or leaked inside information related to the incentive plan.
Announcement is hereby made.
Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.
June 17, 2026